Abbott Labs Files 8-K on Operations and Financials

TL;DR

Abbott Labs filed its 8-K. Standard financial update, no major news.

AI Summary

Abbott Laboratories filed an 8-K on October 16, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or new material events beyond the reporting of these standard items.

Why It Matters

This filing serves as a routine update for investors regarding Abbott Laboratories' operational and financial status, providing transparency on their current condition.

Risk Assessment

Risk Level: low — This is a routine filing reporting on existing financial conditions and operations, not indicating new risks or significant changes.

Key Players & Entities

• ABBOTT LABORATORIES (company) — Registrant
• October 16, 2024 (date) — Date of Report
• Illinois (location) — State of Incorporation
• 100 Abbott Park Road (address) — Principal executive offices
• Abbott Park (location) — City of principal executive offices
• 60064-6400 (zip_code) — Zip code of principal executive offices
• ( 224 ) 667-6 (phone_number) — Registrant's telephone number

FAQ

Filing Documents

• abt-20241016.htm (8-K) — 28KB
• abt-2024q3xexhibitx991.htm (EX-99.1) — 843KB
• abbottlogoa.jpg (GRAPHIC) — 7KB
• 0001628280-24-042893.txt ( ) — 1078KB
• abt-20241016.xsd (EX-101.SCH) — 2KB
• abt-20241016_def.xml (EX-101.DEF) — 15KB
• abt-20241016_lab.xml (EX-101.LAB) — 26KB
• abt-20241016_pre.xml (EX-101.PRE) — 16KB
• abt-20241016_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On October 16, 2024, Abbott Laboratories announced its results of operations for the third quarter 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, a divestiture, restructuring actions, cost reduction initiatives, fair value adjustments to the contingent consideration related to business acquisitions, impairment charges related to intangible assets or equity investments, certain regulatory costs, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit No. Exhibit 99.1 Press Release dated October 16, 2024 (furnished pursuant to Item 2.02). 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: October 16, 2024 By: /s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR